JENGU THERAPEUTICS
Jengu Therapeutics is a biotechnology company founded by Benjamin Neel in 2020. The company conducts research focuses on cellular signaling pathways regulating normal cell proliferation and differentiation, and how disruption of these pathways can cause human diseases, especially cancer.
JENGU THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Status:
Active
Contact:
858-794-4860
Total Funding:
5 M USD
Similar Organizations
AQUA Biomaterials
AQUA Biomaterials, a biotech company, provides contract services such as technical advice, product prototyping, and process development.
Biko Biolabs
Biko Biolabs is a research company focused on the intersection of plastic waste and regenerative agriculture.
Casma Therapeutics
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
JOGO Health
JOGO Health is a biotech company focused on digital therepeutics for neuromuscular conditions.
Uqora
Uqora is a biotechnology company focused on urinary tract health.
Current Advisors List
Current Employees Featured
Founder
More informations about "Jengu Therapeutics"
Jengu Therapeutics - Funding, Financials, Valuation & Investors
Jengu Therapeutics is a biotech company focuses on cellular signaling pathways regulating normal cell proliferation and differentiation.See details»
Jengu Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Jengu Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Jengu Therapeutics - Contacts, Employees, Board Members
Jengu Therapeutics is a biotech company focuses on cellular signaling pathways regulating normal cell proliferation and differentiation.See details»
JENGU THERAPEUTICS, A World Intellectual Property Organization ...
The JENGU THERAPEUTICS trademark was assigned an Application Number # 1564138 by the World Intellectual Property Organization (WIPO). Trademark Application Number is a Unique …See details»
Jengu Therapeutics, Inc. | CipherBio
Explore Jengu Therapeutics, Inc.'s investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Jengu Company Profile 2024: Valuation, Funding
Jengu General Information Description. Developer of a micro-fluid testing device designed to detect and reduce food spoilage. The company's small portable micro-fluid tester is a pocket-sized, battery-powered device that detects …See details»
Combination of Experimental Drug Classes Shown to Extend
Aug 5, 2021 Other study co-investigators are John Zebala and Dean Maeda of Syntrix Pharmaceuticals, James Christensen and Peter Olson of Mirati Therapeutics, Argus Athanas …See details»
Simulated Chemistry: New AI Platform Designs …
May 6, 2024 Disclosures: Trey Ideker is a scientific co-founder, consultant, and advisory board member with equity and income with Data4Cure, Inc, Ideaya Biosciences, Inc., Serinus Biosciences Inc., and Jengu Therapeutics, Inc.See details»
Jengu Therapeutics - Crunchbase
Jengu Therapeutics is a biotech company focuses on cellular signaling pathways regulating normal cell proliferation and differentiation.See details»
Combination of Experimental Drug Classes Shown to …
Aug 5, 2021 Neel holds equity in, and receives consulting fees from, Navire Pharma and Jengu Therapeutics, and holds equity in Northern Biologics, Arvinas, and Recursion. He also has a sponsored research agreement with Mirati and …See details»
Vitamin C Enhances PARPi Efficacy for the Treatment of AML
Nov 5, 2021 Neel: Northern Biologics, LTD: Current equity holder in publicly-traded company, Other: Co- Founder; SAB: Other: Co-Founder; Navire Pharma: Consultancy, Current equity …See details»
Dual targeting of JAK2 and ERK interferes with the …
Sep 3, 2021 GH is co-founder and shareholder of Incephalo AG, received consulting honoraria from Novartis and B. Braun AG, and received research grants from Novartis Research …See details»
Early cross-coronavirus reactive signatures of protective humoral ...
May 12, 2021 A.S.M, and E.R.M. are employees of Space Exploration Technologies Corp. E.S.F. is a founder, scientific advisor and equity holder for: Jengu Therapeutics (board …See details»
Jengu Therapeutics - Updates, News, Events, Signals & Triggers
Jengu Therapeutics is a biotech company focuses on cellular signaling pathways regulating normal cell proliferation and differentiation. Search Crunchbase. Start Free Trial . Chrome …See details»
Dual inhibition of SHP2 and autophagy suppresses NF1 ... - bioRxiv
Aug 18, 2022 The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in …See details»
Machine learning modeling of protein-intrinsic features predicts ...
Sep 29, 2021 E.S.F. is a founder, science advisory board (SAB) member, and equity holder in Civetta Therapeutics, Jengu Therapeutics (board member), Neomorph Inc and an equity …See details»
Jengu Therapeutics - Tech Stack, Apps, Patents & Trademarks
Organization. Jengu Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Patents and Trademarks by IPqwery. Edit …See details»
Seed Round - Jengu Therapeutics - 2020-09-23 - Crunchbase
Sep 23, 2020 Jengu Therapeutics raised $5000000 on 2020-09-23 in Seed Round. Start Free TrialSee details»
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2 ...
Oct 13, 2021 Footnotes. ↵ * These authors contributed equally.. Competing interests: B.G.N. is a founder of, shareholder in, and receives consulting fees from Navire Pharma and Jengu …See details»